Angel News

Angel News

Back to Homepage

21st August 2019

Calculus extis investment in Synpromics exceeding target returns for investors

Scottish biotech company, and the market leader in gene therapy control technologies, Synpromics, has been bought by AskBio, the American pioneer in gene therapeutics.  EIS and VCT fund manager Calculus Capital, which first invested in Synpromics in 2015 and invested £5.6m into the company in total, will receive a return on investment that significantly exceeds target returns.

...

Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:

Name:

Email:

Comment:

Enter the characters in the image shown:



Back to Homepage